Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy
- PMID: 31372078
- PMCID: PMC6628137
- DOI: 10.2147/JBM.S166780
Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy
Abstract
Introduction: Venous thromboembolism (VTE) is a potential risk of estrogen therapy. However, data show an improvement in the quality of life for transgender people who use feminizing hormone therapy. With few transgender-specific data, guidance may be drawn from cisgender (nontransgender) data, with a focus on hormonal birth control and postmenopausal hormone replacement therapy (HRT). The aim of this review is to examine the degree to which routes of administration, patient comorbidities, and type of hormone utilized affect the safety of estrogen therapy. Methods: We identified 6,349 studies by searching PubMed with the terms "transgender", "estrogen", "VTE", and "HRT". Of these, there were only 13 studies between 1989 and 2018 that investigated the effects of hormone therapy, including types of estrogens used, in transgender women and men. Results: The data suggest that the route of hormone administration, patient demographics, and patient comorbidities all affect estrogen's link with VTE. For example, avoiding ethinyl estradiol might make the use of hormone therapy in trans feminine individuals safer than oral birth control. Data from both cis and trans groups suggest additional VTE risk associated with the use of progestins. While transdermal estrogens dosed up to 0.1 mg/day or below appear lower risk for VTE than other forms of estrogen, it is unclear whether this is related to the delivery method or a dose effect. Finally, even if the risk from exogenous estrogen use remains significant statistically, the absolute clinical risk remains low. Conclusion: Clinicians should avoid the use of ethinyl estradiol. Additionally, data suggest that progestins should be avoided for transgender individuals. Further study of the relationship between estrogen use and the risk of VTE will serve to inform the safest care strategies for transgender individuals.
Keywords: estrogen therapy; transgender; venous thromboembolism.
Conflict of interest statement
Dr Joshua D Safer was a member of an Advisory Board for Endo Pharmaceuticals, June, 2018. The authors report no other conflicts of interest in this work.
Similar articles
-
Minimizing Venous Thromboembolism in Feminizing Hormone Therapy: Applying Lessons From Cisgender Women and Previous Data.Endocr Pract. 2021 Jun;27(6):621-625. doi: 10.1016/j.eprac.2021.03.010. Epub 2021 Apr 2. Endocr Pract. 2021. PMID: 33819637 Review.
-
Risk for Venous Thromboembolism in Transgender Patients Undergoing Cross-Sex Hormone Treatment: A Systematic Review.J Sex Med. 2021 Jul;18(7):1280-1291. doi: 10.1016/j.jsxm.2021.04.006. Epub 2021 Jun 16. J Sex Med. 2021. PMID: 34140253
-
Risk of Venous Thromboembolism in Transgender People Undergoing Hormone Feminizing Therapy: A Prevalence Meta-Analysis and Meta-Regression Study.Front Endocrinol (Lausanne). 2021 Nov 9;12:741866. doi: 10.3389/fendo.2021.741866. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34880832 Free PMC article.
-
Stroke and Blood Clot Risk in Transgender Women Taking Hormones [Internet].Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 May. Washington (DC): Patient-Centered Outcomes Research Institute (PCORI); 2021 May. PMID: 37527367 Free Books & Documents. Review.
-
Venous thromboembolism in the hormonal milieu.Curr Opin Hematol. 2020 Sep;27(5):327-332. doi: 10.1097/MOH.0000000000000599. Curr Opin Hematol. 2020. PMID: 32740039 Review.
Cited by
-
Thrombophilia and hormonal therapy in transgender persons: A literature review and case series.Int J Transgend Health. 2022 Jan 20;23(4):377-391. doi: 10.1080/26895269.2022.2025551. eCollection 2022. Int J Transgend Health. 2022. PMID: 36324880 Free PMC article.
-
Assessment of parenteral estradiol and dihydroxyprogesterone use among other feminizing regimens for transgender women: insights on satisfaction with breast development from community-based healthcare services.Ann Med. 2024 Dec;56(1):2406458. doi: 10.1080/07853890.2024.2406458. Epub 2024 Sep 20. Ann Med. 2024. PMID: 39301885 Free PMC article.
-
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8.Int J Transgend Health. 2022 Sep 6;23(Suppl 1):S1-S259. doi: 10.1080/26895269.2022.2100644. eCollection 2022. Int J Transgend Health. 2022. PMID: 36238954 Free PMC article.
-
An Observational Study of Hypertension and Thromboembolism Among Transgender Patients Using Gender-Affirming Hormone Therapy.Transgend Health. 2020 Mar 16;5(1):1-9. doi: 10.1089/trgh.2019.0061. eCollection 2020 Mar 1. Transgend Health. 2020. PMID: 32322683 Free PMC article.
-
Estradiol Therapy in the Perioperative Period: Implications for Transgender People Undergoing Feminizing Hormone Therapy.Yale J Biol Med. 2020 Sep 30;93(4):539-548. eCollection 2020 Sep. Yale J Biol Med. 2020. PMID: 33005118 Free PMC article. Review.
References
-
- Hess J, Breidenstein A, Henkel A, et al. Satisfaction, quality of life and psychosocial resources of male to female transgender after gender reassignment surgery. Eur Urol Suppl. 2018;17(2):e1748. doi:10.1016/S1569-9056(18)32062-1 - DOI
-
- James S. E., et al. The report of the 2015 U.S. Transgenderr Survey. National Center for Transgnder Equality; 2016. Available from: https://transequality.org/sites/default/files/docs/usts/USTS-Full-Report.... Accessed June 10, 2019.
-
- Heylens, Gunter, Verroken C, De Cock S, T'Sjoen G, De Cuypere G. Effects of different steps in gender reassignment therapy on psychopathology: a prospective study of persons with a gender identity disorder. J Sex Med. 2014;11(1):119–126. - PubMed
LinkOut - more resources
Full Text Sources